SAFETY ASSESSMENT CONSIDERATIONS FOR ANTIBODY DRUG CONJUGATES

被引：0
|
作者：
Hinkle, Beth [1 ]
机构：
[1] Amgen Inc, Thousand Oaks, CA USA
来源：
DRUG METABOLISM REVIEWS | 2012年 / 44卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：23 / 24
页数：2
相关论文
共 50 条
  • [31] Preclinical and clinical pharmacokinetic/pharmacodynamic considerations for antibody-drug conjugates
    Sapra, Puja
    Betts, Alison
    Boni, Joseph
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2013, 6 (05) : 541 - 555
  • [32] Biosimilar antibody drug conjugates: considerations of higher order structure and aggregation
    Easton, Richard L.
    GABI JOURNAL-GENERICS AND BIOSIMILARS INITIATIVE JOURNAL, 2023, 12 (03):
  • [33] Considerations for Starting Material Designation for Drug-Linkers in Antibody-Drug Conjugates
    Jones, Michael T. T.
    Dirat, Olivier
    Conlon, David A. A.
    Melucci, Charles
    Schrier, Kate
    Raglione, Thomas
    Zhang, Qunying
    Bulger, Paul G. G.
    ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2023, 27 (07) : 1269 - 1275
  • [34] Antibody drug conjugates
    Bala, Stalin
    Prasad, K. Siva
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2020, 41 (06) : 889 - 892
  • [35] Antibody–drug conjugates
    Rachel S. Zolot
    Satarupa Basu
    Ryan P. Million
    Nature Reviews Drug Discovery, 2013, 12 : 259 - 260
  • [36] Antibody drug conjugates
    Ray Bakhtiar
    Biotechnology Letters, 2016, 38 : 1655 - 1664
  • [37] Antibody drug conjugates
    Bakhtiar, Ray
    BIOTECHNOLOGY LETTERS, 2016, 38 (10) : 1655 - 1664
  • [38] Antibody drug conjugates
    Teicher, Beverly A.
    Teicher, Beverly A.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2013, 246
  • [39] Antibody drug conjugates
    Teicher, Beverly A.
    CURRENT OPINION IN ONCOLOGY, 2014, 26 (05) : 476 - 483
  • [40] Challenges and advances in the assessment of the disposition of antibody-drug conjugates
    Kamath, Amrita V.
    Iyer, Suhasini
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2016, 37 (02) : 66 - 74
12345